Personalised Medicine

ETH researchers have developed a new gene switch that can be activated using a commercially available nitroglycerine patch applied to the skin. One day, researchers want to use switches of this kind to trigger cell therapies for various metabolic diseases.

Scientists at EPFL have developed "lymphomoids," a pioneering cancer model that preserves the structure and multicellular composition of lymphoma tumors in the lab. Lymphomoids offer an innovative way to test the efficacy of lymphoma treatments and better predict individual responses.

Not all pain is the same. Depending on the cause, it requires different therapies. A team led by ETH Zurich has now developed a method that enables physicians to better distinguish between physical and psychosocial pain.

Addressing problems with diagnosing and treating breast cancer, scientists at EPFL have developed EMBER, a tool that integrates breast cancer transcriptomic data from multiple databases. EMBER can improve precision oncology by accurately predicting molecular subtypes and therapy responses.

Using machine-learning methods, researchers at ETH Zurich have shown that more than half of all killer T cells exhibit nuclear invaginations, or folds in the cell’s nuclear envelope. Thanks to this particular cellular architecture, such cells are able to mount a faster and stronger response to pathogens.